

Ipsen

2013 Financial Results

Bryan Garnier Roadshow – April 2014



Disclaimer

This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management's current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated in the summary information. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably given that a new product can appear to be promising at a preparatory stage of development or after clinical trials but never be launched on the market or be launched on the market but fail to sell notably for regulatory or competitive reasons. The Group must deal with or may have to deal with competition from generic that may result in market share losses, which could affect its current level of growth in sales or profitability. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this presentation to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based unless so required by applicable law.

All product names listed in this document are either licensed to the Ipsen Group or are registered trademarks of the Ipsen Group or its partners.

The implementation of the strategy has to be submitted to the relevant staff representation authorities in each country concerned, in compliance with the specific procedures, terms and conditions set forth by each national legislation.

Safe Harbor

The Group operates in certain geographical regions whose governmental finances, local currencies or inflation rates could be affected by the current crisis, which could in turn erode the local competitiveness of the Group's products relative to competitors operating in local currency, and/or could be detrimental to the Group's margins in those regions where the Group's drugs are billed in local currencies.

In a number of countries, the Group markets its drugs via distributors or agents: some of these partners' financial strength could be impacted by the crisis, potentially subjecting the Group to difficulties in recovering its receivables. Furthermore, in certain countries whose financial equilibrium is threatened by the crisis and where the Group sells its drugs directly to hospitals, the Group could be forced to lengthen its payment terms or could experience difficulties in recovering its receivables in full.

Finally, in those countries in which public or private health cover is provided, the impact of the financial crisis could cause medical insurance agencies to place added pressure on drug prices, increase financial contributions by patients or adopt a more selective approach to reimbursement criteria.

All of the above risks could affect the Group's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today.

Agenda

1

2013 overview

2

2013 performance

3

US update

4

2014 outlook

2013 operating margin above guidance, despite sales headwinds

	2013 initial guidance ⁽¹⁾	2013 revised guidance ⁽²⁾	2013 actuals
Specialty Care - Drug sales ^(*)	[6.0% ; 8.0%]	~ +3.0%	+3.0% ✓
Primary Care - Drug sales ^(*)	[-8.0% ; -6.0%]	~ (1.0)%	(0.1%) ✓
Recurring Adjusted ^(**) operating margin	~ 16.0%	~ 16.0%	17.0% ✓

Note: The above sales objectives were set at constant currency

2013, acceleration of transformation and major clinical successes

Enhanced R&D
delivery and focus

Four Phase III programs delivered

Major step forward in toxin research and Intellectual Property
with Syntaxin acquisition and Harvard partnership

Acceleration of
transformation

Christel Bories appointed Deputy CEO

Split of Primary and Specialty Care


New focus on efficiency and cost control
(Successful restructuring of French PC and US Dysport® operations)

In 2013, Ipsen delivered four Phase III on Dysport® and Somatuline®

Clinical development phase	Data published	Molecule/Drug
Phase III	Full results	Dysport® Next Generation – CD – Europe ✓
Phase III	Full results	Dysport® AUL Spasticity ✓
Phase III	Full results	Somatuline® in NET tumor control – WW – (CLARINET®) ✓
Phase III	Full results	Somatuline® in NET symptom control – US – (ELECT®) ✓
Phase II	Full results	Dysport® Next Generation – GL – Europe ✓

Ipsen share price up 50% in 2013, reflecting good momentum

Share price (€)




Note: SBF 120 and STOXX Europe TMI Pharma. have been rebased at Ipsen share price of 02/01/2013

2013 performance

Above EBIT

Specialty care sales growth affected by Decapeptyl[®] performance and Increlex[®] shortage

Drug sales – FY 2013 in million euros – % excluding foreign exchange impact




Increlex[®] resupplied in Europe in 2014

2013 sales driven by international primary care and specialty care

FY sales
in million euros


GROUP SALES growth: +0.4% (incl. Drug related sales)
At constant currency: +2.2%





Continued strategic focus on growth drivers

Specialty care volume growth driven by Somatuline[®] and Dysport[®], affected by Decapeptyl[®] performance

2013 volume and value growth




2013 geographic distribution



Dynamic international growth, France now down to 30% of primary care sales

Evolution of Primary care sales




Primary care sales in M€⁽²⁾ ▶ 384 390 393 383 380 364 368 325 320

Two 7.5% consecutive price cuts on Smecta[®] in France in 2014


Remaining overhang: Risk of Smecta[®] generic in France

Ipsen growth fuelled by a differentiated emerging market footprint, soon to be supported by the US

Ipsen largest affiliates




Ipsen geographical split



Ipsen among the pharma companies with the strongest presence in emerging markets

In the context of 2013 lower sales growth, tight Opex control allowed to finance R&D while growing EBIT margin




Note: 2012 figures have been restated to provide comparative information between 2012 and 2013
⁽¹⁾ As reported – ⁽²⁾ Restated from OBI-1-related costs – ⁽³⁾ Prior to non-recurring elements



From reported to Recurring adjusted Operating Income


FY 2012

In million euros



FY 2013

In million euros



Note: 2012 figures have been restated to provide comparative information between 2012 and 2013



2013 performance

Below EBIT

P&L summary

<i>in m€</i>	FY 2012 restated*	FY 2013	Change
Net sales	1,219.5	1,224.8	+0.4%
Other revenues	57.9	57.0	(1.5)%
Revenue	1,277.4	1,281.8	+0.3%
Cost of goods sold	(254.3)	(253.4)	(0.4)%
Research and development expenses	(248.2)	(259.1)	+4.4%
Selling expenses	(473.0)	(451.3)	(4.6)%
General and administrative expenses	(99.1)	(103.8)	+4.8%
Operating income	117.1	190.7	+62.9%
Operating margin	9.6%	15.6%	
Recurring adjusted⁽¹⁾ operating profit	198.3	208.6	+5.2%
Recurring adjusted⁽¹⁾ operating margin	16.3%	17.0%	
Financial Result	5.4	(9.0)	N/A
Income taxes	(25.2)	(39.6)	N/A
Consolidated profit	(27.5)	153.1	N/A
Recurring adjusted⁽¹⁾ EPS – fully diluted (€)	1.76	1.85	+5.1%


Note: 2012 figures have been restated to provide comparative information between 2012 and 2013
⁽¹⁾ Prior to non-recurring elements

Main P&L items: Below operating income


Financial Result (€m)




Effective tax rate



Net income from discontinued operations (€m)



EPS (€)



Note: 2012 figures have been restated to provide comparative information between 2012 and 2013
⁽¹⁾ Prior to non-recurring elements

Balance sheet evolution

ASSETS			LIABILITIES		
<i>in m€</i>	FY 2012 Restated	FY 2013	<i>in m€</i>	FY 2012 Restated	FY 2013
Goodwill	298.2	310.7	Capital and reserves	902.5	971.5
Investments in associates	0.0	0.0	Minority interest	2.0	2.2
Property, plant and equipment	281.8	287.5	Total equity	904.5	973.7
Other intangible assets	129.2	144.8	Provisions	68.3	90.7
Other non current assets	246.3	220.5	Other financial liabilities	18.4	19.1
Non-current assets	955.5	963.5	Other non current liabilities	133.8	105.6
Current assets	606.3	601.8	Non-current liabilities	220.4	215.4
<i>Incl. Cash and cash equivalents</i>	113.6	131.0	Current liabilities	437.0	376.2
Total Assets	1,561.9	1,565.3	Total Liabilities	1,561.9	1,565.3

Solid cash flow generation

<i>in m€</i>	FY 2012 Restated	FY 2013
Consolidated net profit	(27.5)	153.1
Non cash and non operating items	177.6	56.2
<i>of which Depreciation, amortization, provisions</i>	70.2	25.7
<i>of which Impairment losses</i>	123.1	12.6
<i>of which Change in deferred taxes</i>	(24.1)	8.2
Cash flow from operating activities before changes in working capital	171.8	209.3
Net change in other operating assets & liabilities	(27.6)	(21.1)
Net cash flow generated by operating activities	144.2	188.1
Purchase of tangible and intangible assets	(82.8)	(88.6)
Other	(17.4)	(15.1)
Net cash flow used in investing activities	(100.2)	(103.7)
Dividends paid	(67.5)	(66.9)
DIP and other	(5.7)	(9.6)
Net cash used in financing activities	(73.2)	(76.5)
Opening cash position	144.8	113.3
Change in cash and FX	(31.5)	12.1
Closing cash position	113.3	125.4

Operating cash flow up 30% in 2013

2013: Key financial achievements

Group sales up 2.2%⁽¹⁾

Strong Recurring Adjusted⁽²⁾ Operating margin of 17%⁽³⁾

Net profit of €153.1m versus a (€27.5m) loss in 2012

Robust Recurring Adjusted⁽²⁾ EPS of €1.85, up 5.1% year-on-year

Sound operating cash flow generation


Closing cash balance of €125.4m

Proposed dividend of €0.80 per share, stable year-on-year


US update

Increasing US presence, a strategic priority

Global Pharma Market^(*)



Ipsen 2013 sales



US under-represented in Ipsen sales

Reaching critical mass in the US is key to drive Group profitability

⁽¹⁾ France, Germany, UK, Italy, Spain – ⁽²⁾ Notably includes China, Russia and Brazil
^(*) Source: Ipsen estimates and IMS Health Market Prognosis, September 2013 (US\$ spending with variable exchange rates)

Somatuline[®] well positioned in the US to seize significant NET opportunity

Favorable competitive position


Differentiated NET data package with CLARINET[®]

Strong position gained in acromegaly⁽¹⁾ with ~ 50% market share

Differentiated product/presentation

Long acting formulation setting barrier for potential new entrants

Potential addressable market (2013)



Ipsen to launch Somatuline[®] in NET indication in the US to capture full value

Rationale

Secure long term value

Secure Ipsen US strategic presence

Build long term presence in US oncology

Maintain full control over decisions

Leverage global product expertise

Impact

- Expected maximum incremental annual cost of €[30-40]m
- US breakeven⁽¹⁾ postponed to 2017

Cynthia Schwalm to manage US operations and secure Somatuline[®] NET launch

Cynthia Schwalm



- 30 years of experience in oncology and neurology
- In-depth knowledge of the American pharmaceutical market
- Appointed Head of Ipsen's US Endocrinology/Oncology Business Unit
- To become US General Manager as of mid-August 2014

Key challenges

Build US oncology sales force

Secure Somatuline[®] GEP NET label

Manage Increlex[®] shortage

Ipsen committed to succeed in the US

2014 outlook

2014 financial objectives

Specialty care – Drug sales

Growth of +4.0% to +6.0%, year-on-year

- *Driven by normalization of situation in China, in a context of continued pricing pressure and uncertainty on Increlex[®] US resupply*

Primary care – Drug sales

Decline of -2.0% to 0.0%, year-on-year

- *Excluding the launch of a Smecta[®] generic in France*

Recurring Adjusted⁽¹⁾ operating margin

Between 16.0% and 17.0% of sales


- *In 2014, Ipsen will continue to implement operating efficiency measures*
- *The Group notably strives to limit the profitability impact of launching Somatuline[®] NET in the US*

Note: All the above objectives are set at constant currency and exclude major negative unforeseeable events, for instance the deterioration in the economic environment in Ukraine
(1) Prior to non-recurring elements

Moving parts to impact 2014 EBIT

Illustrative chart

Evolution of EBIT margin at constant currency



Improved cost control to offset cost inflation and NET US investment

Major R&D and regulatory milestones to come in 2014

	H1 2014	H2 2014	2015
R&D	Tasquinimod mCRPC PhIII results (PFS and OS data)		TasQ maintenance study PhIIa (POC) results
	Dysport® NDO Full PhII data	Tasquinimod (HCC, RCC, Gastric & Ovarian) PhII results ⁽¹⁾	
	Dysport® NG PhIII (CD) and PhII (GL)	Dysport® PLL PhIII topline data	Dysport® PUL PhIII topline data
	Dysport® AUL Full PhIII data	Dysport® ALL PhIII topline data	Dysport® AUL US launch
Regulatory/ Commercial		DNG regulatory feedback	
		Dysport® AUL US filing	
	Somatuline® GEP NETs WW filing	Somatuline® GEP NETs Preparation for US launch	Somatuline® GEP NETs WW launch

Note: NDO: Neurogenic Detrusor Overactivity, GL: Glabellar Lines, CD: Cervical Dystonia, AUL: Adult Upper Limb, HCC: Hepatocellular Carcinoma, RCC: Renal Cell Carcinoma, PLL: Pediatric Lower Limb, ALL: Adult Lower Limb, PUL: Pediatric Upper Limb – ⁽¹⁾ Provided that all futility analyses are completed

In 2014, continued business development efforts to complement organic growth

Areas of focus

Commercial deals


- In-licensing or acquisition of marketed drugs
- Acquisition of small companies
- Various geographies targeted, notably the US

R&D deals


- Late stage compounds (Phase III) in various therapeutic areas
- Early stage compounds (Phase I and II) with a potential for breakthrough innovation

Significant increase in free float with Mayroy's sale of 7% of Ipsen's share capital to finance exit of Véronique Beaufour

Ipsen share capital before placement



Ipsen share capital⁽¹⁾ after placement



Véronique Beaufour not involved in Ipsen's strategy/management

Ipsen purchased 1% of its share capital via the placement

Enhancement of Ipsen's liquidity

⁽¹⁾Taking into account the cancellation of the 842 542 Ipsen shares purchased via the placement and the cancellation of the 800 000 shares purchased as part of the program announced on 6 November 2013

Key takeaways

2013

Strong operating performance and major clinical successes setting the stage for future growth



2014

TasQ phIII clinical results, preparation of NET US launch and continued operating efficiencies

Back up

Over the last decade, Ipsen has succeeded in adapting to a fast changing environment



Drug sales by segment



CAGR⁽¹⁾ 2002-2013

Primary care ⁽²⁾	-1%
Specialty care	+11%


Drug sales by geography



CAGR⁽¹⁾ 2002-2013

France	-3%
Emerging markets ⁽³⁾	+17%
Rest of the world	+7%

Ipsen ambitions to become a global leader in targeted debilitating diseases



The new strategy implemented by Marc de Garidel since 2011 involved key decisions

Increase focus

- Close R&D activities at Barcelona site
- Terminate one third of R&D projects
- Regions and countries to manage Short Stature in commercial optimization perspective
- Explore new commercial partnership opportunities in French primary care
- Ensure sustainable future to Dreux manufacturing site


Focus on 3 key franchises to drive innovation

	Research & Development	Manufacturing	Operations	2013 sales growth ⁽¹⁾
Somatuline[®] Endocrinology	✓	✓	✓	+11.1% €247m
Dysport[®] Neurology	✓	✓	✓	+7.0% €242m
Decapeptyl[®] Uro-oncology	✓	✓	✓	(1.9%) €299m

Primary care and Short Stature in a commercial optimization strategy

⁽¹⁾ Year-on-year sales growth at constant exchange rates

Demonstration of antiproliferative effect of Somatuline® in the treatment of GEP-NETs




Key results

- 62% of GEP-NET patients treated with Somatuline® had not progressed or died versus 22% with placebo
- Disease progression or death was reduced by 53%
- Antiproliferative effect of Somatuline® is:
 - statistically significant in midgut tumors
 - clinically relevant in pancreatic NETs
 - independent of the tumor grade and hepatic tumor load

CLARINET, the first global and differentiated study showing strong results in the treatment of GEP-NETs

Note: P-value derived from stratified log-rank test; HR derived from Cox proportional hazard model. HR, hazard ratio; ITT, intention-to-treat – Primary endpoint: PFS (ITT population, N=204)

Ipsen's R&D toxin platform significantly reinforced by Syntaxin acquisition



Highly complementary acquisition


Integration on track

Positive initial results for Dysport® in Adult Upper Limb spasticity

Initial results

- 243 adult hemiparetic spastic patients
- Multicentric, prospective, double blind, randomised, and placebo-controlled
- Treatment with Dysport® showed a statistically significant and clinically meaningful improvement in:
 - Muscle tone
 - Clinical benefit
- Safety profile consistent with the known safety profile of Dysport®

Potential expansion of Dysport® indications in the US



Full results to be disclosed in the coming months at major international congresses

Ipsen, potentially the first company to launch a ready-to-use toxin A with Dysport® Next Generation



Key characteristics

- First ready-to-use toxin A formulation
- Full product range
- Improved focus on patient care
- Ability to reach more patients in need of treatment

2 separate regulatory pathways

Europe

- Acceptance of several formulations per API
- Equivalence to be demonstrated between both formulations of the same toxin

US


- One single formulation accepted per API
- Interchangeability of formulations to be addressed

Ipsen's R&D reinforced through partnerships



Tasquinimod, an illustration of Ipsen's R&D open model

Tasquinimod, a new first-in-class oral anti-cancer therapy



A unique MoA targeting the tumor's microenvironment,
mainly by binding the S100A9 protein

Tasquinimod, potentially a new therapeutic option for chemo naïve patients
with metastatic CRPC